James C-H Yang
Overview
Explore the profile of James C-H Yang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
1753
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cho B, Lu S, Felip E, Spira A, Girard N, Lee J, et al.
N Engl J Med
. 2024 Jun;
391(16):1486-1498.
PMID: 38924756
Background: Amivantamab plus lazertinib (amivantamab-lazertinib) has shown clinically meaningful and durable antitumor activity in patients with previously untreated or osimertinib-pretreated (epidermal growth factor receptor)-mutated advanced non-small-cell lung cancer (NSCLC). Methods:...
2.
Planchard D, Janne P, Cheng Y, Yang J, Yanagitani N, Kim S, et al.
N Engl J Med
. 2023 Nov;
389(21):1935-1948.
PMID: 37937763
Background: Osimertinib is a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) that is selective for EGFR-TKI-sensitizing and T790M resistance mutations. Evidence suggests that the addition of chemotherapy may extend...
3.
Kim E, Melosky B, Park K, Yamamoto N, Yang J
Future Oncol
. 2021 Apr;
17(18):2395-2408.
PMID: 33855865
Few data are available that have compared outcomes with different EGFR tyrosine kinase inhibitors (TKIs) specifically in Asian patients with mutation-positive non-small-cell lung cancer. In this narrative review, we have...
4.
Park K, Ozguroglu M, Vansteenkiste J, Spigel D, Yang J, Bajars M, et al.
Lung Cancer
. 2021 Feb;
154:92-98.
PMID: 33636453
Objectives: The JAVELIN Lung 200 phase 3 trial did not meet its primary endpoint of improving overall survival (OS) with avelumab vs docetaxel in patients with platinum-treated PD-L1+ NSCLC. We...
5.
Nazha B, Yang J, Owonikoko T
Future Oncol
. 2020 Nov;
17(8):965-977.
PMID: 33242257
While randomized controlled trials (RCTs) are the gold standard for evidence-based medicine, they do not always reflect real-world patient populations, limiting their generalizability and external validity. Real-world evidence (RWE), generated...
6.
Hochmair M, Morabito A, Hao D, Yang C, Soo R, Yang J, et al.
Future Oncol
. 2020 Aug;
16(34):2799-2808.
PMID: 32854536
Final overall survival (OS) and time on treatment analysis of patients with mutation-positive non-small-cell lung cancer (NSCLC) who received sequential afatinib and osimertinib. Patients (n = 203) had T790M-positive disease...
7.
Paik P, Felip E, Veillon R, Sakai H, Cortot A, Garassino M, et al.
N Engl J Med
. 2020 May;
383(10):931-943.
PMID: 32469185
Background: A splice-site mutation that results in a loss of transcription of exon 14 in the oncogenic driver occurs in 3 to 4% of patients with non-small-cell lung cancer (NSCLC)....
8.
Tan D, Leighl N, Riely G, Yang J, Sequist L, Wolf J, et al.
Lancet Respir Med
. 2020 Jan;
8(6):561-572.
PMID: 31954624
Background: Resistance to first-generation and second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) is mediated by the emergence of the Thr790Met mutation in 50-60% of treated patients with...
9.
Yang C, Liao W, Ho C, Chen K, Tsai T, Hsu C, et al.
Eur J Cancer
. 2019 Nov;
124:110-122.
PMID: 31760310
Introduction: Besides being a predictive biomarker of response to immunotherapy in lung cancer in general, programmed death-ligand 1 (PD-L1) is not so well correlated with treatment outcomes of lung adenocarcinoma...
10.
Hochmair M, Morabito A, Hao D, Yang C, Soo R, Yang J, et al.
Future Oncol
. 2019 Aug;
15(25):2905-2914.
PMID: 31370698
Overall survival (OS) and updated time to treatment failure (TTF) analysis of patients with mutation-positive (Del19, L858R) non-small-cell lung cancer who received sequential afatinib/osimertinib in the real-world GioTag study. Patients...